About Acceleron Pharma
Acceleron Pharma (NASDAQ:XLRN) is a biopharmaceutical company focused on developing, manufacturing, and commercializing protein therapeutics for orphan diseases and cancer. It utilizes biotherapeutic technologies and capitalizes on the company's internal GMP manufacturing capability to develop its therapeutic programs. The company was founded in 2003 and is based in Cambridge, Massachusetts. In November 2021, Acceleron Pharma was acquired by Merck & Co..5B.
Missing: Acceleron Pharma's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Acceleron Pharma's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Acceleron Pharma
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Acceleron Pharma is included in 2 Expert Collections, including Cancer.
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Acceleron Pharma Patents
Acceleron Pharma has filed 1 patent.
Transcription factors, Cattle breeds, Developmental genes and proteins, Human proteins, Proteins
Transcription factors, Cattle breeds, Developmental genes and proteins, Human proteins, Proteins
Latest Acceleron Pharma News
Dec 5, 2022
Disclosures: Mclaughlin reports serving as a steering committee member, as well as receiving consultant fees, and research grants/support from Janssen; receiving consultant fees and research grants/support from Acceleron Pharma, Bayer and United Therapeutics; receiving consultant fees from Altavant Sciences, Caremark, CiVi Biopharma and Gossamer Bio; and receiving research grants/support from Reata Pharmaceuticals and SoniVie. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact firstname.lastname@example.org . Back to Healio Macitentan showed no new safety signals in patients with pulmonary arterial hypertension from two real-world datasets, according to a study published in Pulmonary Circulation. The FDA approved macitentan (Opsumit, Actelion Pharmaceuticals), an oral endothelin receptor antagonist, in 2013 with a postmarketing requirement to further evaluate the drug’s safety profile with regard to serious hepatic risks. The OPsumit Users Registry (OPUS) and the OPsumit Historical Users cohort (OrPHeUS) medical chart review were established to fulfill this requirement and to characterize the safety profile of macitentan. Data were derived from McLaughlin VV, et al. Pulm Circ. 2022;doi:10.1002/pul2.12150. “The combined OPUS/OrPHeUS dataset is the largest new‐users database for macitentan, describing a large population of patients who newly initiated macitentan in real‐world clinical practice in the United States,” Vallerie V. Mclaughlin, MD, professor of cardiovascular disease and internal medicine at the University of Michigan Health, and colleagues wrote. “Importantly, this patient population reflects the full heterogeneity of the pulmonary arterial hypertension disease state, including patients with different disease severities, etiologies, and times from diagnosis. The dataset included patients typically excluded from clinical trials due to stringent eligibility criteria, such as those with portopulmonary hypertension or elevated baseline liver function tests.” In a combined data analysis, Mclaughlin and colleagues analyzed 4,626 (median age, 62 years; 75.5% women; 75.9% white) patients with pulmonary arterial hypertension (PAH) to observe safety, and they used Kaplan-Meier estimates to evaluate hospitalization and survival outcomes following treatment with macitentan . The datasets also included an additional 1,024 patients without PAH who initiated macitentan treatment. Of those diagnosed with PAH, researchers found that 54.8% of patients had idiopathic PAH and 26.8% of patients had PAH associated with connective tissue disease. Researchers also found that 57% of patients belonged in WHO functional class III and 37.7% fell into the intermediate-risk category according to BNP/NT-proBNP plasma levels. Median duration of exposure to macitentan was 13.6 months overall and 14.5 months among patients with PAHI. Researchers reported that 42.7% of patients with PAH discontinued the treatment, with 17.1% stopping due to a non-hepatic adverse event, 0.3% due to a hepatic adverse event, 18.1% due to something not related to an adverse event and 7.2% had a missing reason. Initially, 37.9% of patients received macitentan as a monotherapy, 48% received it as a double therapy and 14.1% received it as a triple therapy. However, by 6 months, only 30% of patients received it as monotherapy, whereas 50% received it as double therapy and 20% received it as triple therapy, according to researchers. When evaluating the safety of the treatment, researchers observed no new safety signals, which they wrote is consistent with the largest clinical trial on macitentan, the SERAPHIN study, and verifies its safety profile. In the overall dataset, 9.9% of patients experienced at least one hepatic adverse event and 6.2% experienced at least one serious hepatic adverse event. According to researchers, 59.9% (95% CI, 58.3-61.5) of patients with PAH were out of the hospital and 90.4% (95% CI, 89.3-91.3) survived at 1 year. Both of these percentages were comparable for patients with idiopathic/heritable PAH and patients with connective tissue disease. At the 3-year mark, researchers reported that 75% (95% CI, 73-77) of patients with PAH were still alive, which was also comparable to patients with idiopathic/heritable PAH and patients with connective tissue disease. “Macitentan was well tolerated in clinical practice with overall and hepatic safety profiles consistent with previous macitentan clinical trials,” Mclaughlin and colleagues wrote. “Further investigation into why combination therapy is not more frequently used in this contemporary era is necessary.” Read more about
Acceleron Pharma Web Traffic
Acceleron Pharma Rank
Acceleron Pharma Frequently Asked Questions (FAQ)
When was Acceleron Pharma founded?
Acceleron Pharma was founded in 2003.
Where is Acceleron Pharma's headquarters?
Acceleron Pharma's headquarters is located at 128 Sidney Street, Cambridge.
What is Acceleron Pharma's latest funding round?
Acceleron Pharma's latest funding round is Acq - P2P.
How much did Acceleron Pharma raise?
Acceleron Pharma raised a total of $136.52M.
Who are the investors of Acceleron Pharma?
Investors of Acceleron Pharma include Merck & Co., Novo Ventures, Flagship Pioneering, Sutter Hill Ventures, Advanced Technology Ventures and 13 more.
Who are Acceleron Pharma's competitors?
Competitors of Acceleron Pharma include Dare Bioscience, AM-Pharma, Array Biopharma, Threshold Pharmaceuticals, ActoGeniX and 12 more.
Compare Acceleron Pharma to Competitors
Iconic Therapeutics is a clinical-stage biopharmaceutical company dedicated to translating scientific knowledge into new medicines. The company's understanding of the role of the tissue factor in angiogenesis, inflammation, and malignancies has led it to a new approach to developing therapies for devastating diseases such as macular degeneration and cancer.
Dare Bioscience is a healthcare company committed to the development and commercialization of innovative products in women's reproductive health. We believe there is an unmet need globally for new product candidates that expand options, improve outcomes and are easy to use. By advancing these products, we seek to expand choices and to make a difference in the lives of women worldwide.
AM-Pharma is a biopharmaceutical company that focuses on the development of recombinant Alkaline Phosphatase for clinical use.
ACUREON Pharmaceuticals is a United States biopharmaceutical company primarily focused on specialty therapeutics to improve patient outcomes in the hospital areas of Infectious Diseases, Transplant, and ICU. To address the needs of the market, Acureon Pharma is focused on exploring opportunities that selectively acquire and enhance the market potential of commercially available therapeutics and late-stage development drugs. The company is located in the western suburbs of Philadelphia.
BIKAM Pharmaceuticals, Inc. is an early stage biopharmaceutical company focusing upon the discovery and development of small molecule therapeutics for the treatment of ophthalmic diseases and disorders, including retinitis pigmentosa. Worldwide, there are approximately 1.5 million people which suffer from retinitis pigmentosa (RP), a hereditary disease which leads to blindness. As its initial priority, the company is pursuing the discovery of compounds based on a novel mechanism of action identified by the company's founder, Dr. Shalesh Kaushal. BIKAM has an experienced management team with a strong track record in pharmaceutical drug discovery dedicated to expanding these findings and others from the Kaushal lab to create potential therapeutics to prevent blindness.
REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat conditions such as allergies, autoimmune diseases and inflammatory disorders.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.